WEBULL
WebtradeDownload

ZACROS (TSE:7917) Stock Price Slides Even As Profit Margins Firm

Simply Wall St · 2d ago

ZACROS stock has drifted lower in recent weeks, yet the latest earnings print delivered a very different message. The share price sits well below its 90 day level, while Q1 2027 earnings per share of ¥35.51 and net income of ¥2,541m paint a picture of a company still generating solid profits. The key story is margin and earnings strength holding up even as sentiment looks tired. Traders focused on the past month’s weakness may be reacting more to mood than to the underlying cash generation on display in this quarter.

Is ZACROS trading at a genuine discount, or is the low P/E simply masking cash flow and dividend coverage issues? Compare the current share price to our detailed valuation analysis for ZACROS

Q1 2027 Earnings Summary

  • Revenue, Q1 2027 vs. Q1 2026: ¥41,420m vs. ¥39,307m (year on year increase)
  • Net Income, Q1 2027 vs. Q1 2026: ¥2,541m vs. ¥2,449m (year on year increase)
  • Basic EPS, Q1 2027 vs. Q1 2026: ¥35.51 vs. ¥33.27 (year on year increase)
  • Net Profit Margin, Trailing 12 Months vs. Prior Year: 4.9% vs. 4.3% (margin higher than prior year)

If you prefer clean charts instead of a wall of earnings tables and raw figures, view ZACROS’ full financial picture and see a visual overview of its recent earnings and profitability trends in the company report for ZACROS.

TSE:7917 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
TSE:7917 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

ZACROS earnings resilience supports cautious optimism

For investors looking at ZACROS as a steady enabler in healthcare and specialty packaging, the latest figures broadly support that view. Revenue and net income are both higher year on year, and basic EPS is also up. The trailing 12 month net margin of 4.9% compared with 4.3% previously points to firmer profitability rather than strain. That aligns with a picture of a diversified industrial and healthcare supplier that continues to convert its product mix into earnings, even while the share price and recent returns suggest sentiment has cooled.

Weak recent returns keep bearish questions alive

The share price tells a more cautious story. ZACROS is down about 6% over 7 days, 2% over 30 days, and close to 9% over 90 days. That weak run, despite positive year on year moves in revenue, net income and EPS, indicates that investors still question how durable current margins are and whether growth across healthcare, packaging and electronics is strong enough. The recent data does not flag immediate earnings stress, yet the market reaction suggests that investors want clearer evidence that this profitability trend can hold through future cycles.

After a share price slide like this, it is fair to ask whether ZACROS has deeper balance sheet or cash flow vulnerabilities. Review the independent risk analysis for ZACROS which shows 1 important warning sign

Stay Ahead With Simply Wall St

If ZACROS looks interesting after its recent earnings strength but softer share price, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch for a better entry point. Once you do own ZACROS or other stocks, keep a clear view of your holdings with the Portfolio Command Center so you can cut through market noise and focus on the updates that matter. For a longer term edge, tap into crowd insights and different viewpoints through the Community. This way you can spot potential catalysts or risks earlier and stay ahead of the market.

Seeking Alternatives Beyond ZACROS?

Fresh ideas do not stay under the radar for long. Some stocks build quiet breakout momentum while others get caught dropping before the crowd reacts. Act now and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.